Novartis Strategy and Business Model

Executive Overview

Novartis is a Basel-headquartered innovative medicines company focused on patented prescription drugs. The company was created in 1996 through the merger of Ciba-Geigy and Sandoz, and it became a more concentrated biopharma company after the spin-off of Sandoz in 2023. Today, Novartis develops and commercializes medicines across cardiovascular, renal and metabolism; immunology; neuroscience; and oncology, using modalities that include small molecules, biologics, radioligand therapy, and gene therapy. In FY2024, Novartis reported net sales of $50.3 billion.

Strategically, Novartis is trying to do fewer things, but do them better. Management has emphasized a focused innovative medicines portfolio, selective bolt-on acquisitions, stronger launch execution, and productivity gains from simplification and digital tools. That strategy is visible in the company’s current growth brands, including Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto, Scemblix, and Fabhalta, as well as in acquisitions such as Chinook, MorphoSys, and Mariana Oncology. Novartis operates globally, with the United States as its largest market and meaningful positions across Europe, China, Japan, and other major pharmaceutical markets. For readers trying to understand the strategy of Novartis, the central point is that it now looks less like a diversified healthcare group and more like a focused, high-margin medicines platform built around science, IP, and disciplined portfolio choices.

Novartis at a Glance

Logo
Common name	Novartis
Full legal name	Novartis AG
Headquarters	Basel, Switzerland
Ownership	Publicly traded; no controlling shareholder was disclosed in the FY2024 Annual Report.
Ticker	NOVN
Exchange	SWX - SIX Swiss Exchange
Market Cap	$385.10B
Revenue (FY2024)	$50.32B
Founding / major historical milestones	Created in 1996 through the merger of Ciba-Geigy and Sandoz; Alcon was spun off in 2019; Sandoz was spun off in 2023, leaving Novartis as a focused innovative medicines company.
Industry or industries	Innovative pharmaceuticals / biopharma
Key products or services	Patented prescription medicines, including Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto, Scemblix, Fabhalta, Lutathera, and Zolgensma
Geographic footprint	Global, with major commercial positions in the United States, Europe, China, Japan, and other major pharmaceutical markets
Business segments as officially reported	One operating segment: Innovative Medicines (FY2024)
Company website	https://www.novartis.com

1. What Is the Strategy of Novartis?

Novartis’s public strategy since the Sandoz separation has been clear: become a more focused innovative medicines company, concentrate capital on high-value science and launches, and use a simpler portfolio to produce faster growth and higher margins. The company’s strategy maps well to the five questions in the Playing to Win framework.

1. 1a. What is the winning aspiration of Novartis?

   Novartis frames its purpose as “reimagining medicine to improve and extend people’s lives,” but the practical winning aspiration is more specific: build one of the industry’s best-performing pure-play innovative medicines companies. In public strategy updates, management has emphasized durable, innovation-led growth, stronger margins, and leadership in selected disease areas rather than broad diversification. Novartis has also communicated medium-term financial ambitions that include about 5% annual sales growth through 2028 and core margin expansion to above 40%, making clear that “winning” means both medical impact and higher-quality economics.

2. 1b. Where does Novartis play?

   Novartis has narrowed its playing field. It now focuses on branded prescription medicines in therapeutic areas where it believes it has scientific depth and commercial scale: cardiovascular, renal and metabolism; immunology; neuroscience; and oncology. Geographically, it plays in the world’s major pharmaceutical markets, especially the United States, Europe, China, and Japan. By spinning off Sandoz in 2023, Novartis explicitly exited large-scale generics as a core business and reinforced its decision to compete where patent-protected innovation, clinical evidence, and specialist commercialization matter most.

3. 1c. How does Novartis plan to win?

   Novartis plans to win by offering differentiated medicines with strong clinical data in large or high-unmet-need markets, then scaling those assets globally through focused launch execution and lifecycle management. The company is not trying to be the broadest healthcare conglomerate. Instead, it is trying to be better at selecting science, allocating capital, and commercializing specialty and large-market brands. Its recipe for winning combines internal R&D, selective external business development, deep disease-area focus, and disciplined portfolio pruning. The strategy also depends on operational execution: expanding radioligand manufacturing, supporting major launches such as Fabhalta and Pluvicto, and improving productivity so more of each sales dollar falls to operating profit.

4. 1d. What capabilities must Novartis have in place?

   To make that strategy work, Novartis needs strong discovery science, translational medicine, clinical development, regulatory execution, and global market access capabilities. It also needs specialized manufacturing capabilities in small molecules, biologics, sterile products, radioligand therapies, and gene therapy. Commercially, Novartis must be able to launch both primary-care-adjacent brands such as Leqvio and specialist drugs such as Kisqali, Kesimpta, Pluvicto, and Scemblix. Increasingly, data, digital, and AI capabilities matter as cross-functional enablers across research, trials, manufacturing, and knowledge work.

5. 1e. What management systems does Novartis require?

   Novartis needs management systems that keep a science-led company commercially disciplined. That includes stage-gated portfolio reviews, rigorous capital allocation, launch governance, quality and pharmacovigilance systems, and enterprise risk controls suited to a regulated global pharma company. It also requires performance systems that track not just sales, but pipeline productivity, manufacturing reliability, compliance, margin progression, and return on business development. After the Sandoz spin-off, simplification itself became a management system objective: fewer layers, clearer accountability, and tighter alignment between portfolio choices and resource allocation.

2. What Are the Current Strategic Initiatives of Novartis?

Based on Novartis’s FY2024 reporting and recent strategy communications, the company’s current strategic initiatives are highly concrete rather than abstract.

• Scale the current growth brands. Novartis is concentrating execution behind brands that can reshape the company’s revenue mix over the next several years, especially Kisqali, Kesimpta, Leqvio, Pluvicto, Scemblix, and Fabhalta, while continuing to maximize large established drivers such as Entresto and Cosentyx.
• Expand indications and move products earlier in treatment lines. In oncology and immunology, label expansions can be as important as new molecular launches. Novartis has been working to broaden use cases for brands such as Kisqali and Pluvicto, which can materially enlarge addressable patient populations if supported by data and reimbursement.
• Build a differentiated radioligand therapy platform. Novartis has made radioligand therapy a strategic priority. That requires not only clinical development, but also manufacturing, isotope handling, site-of-care enablement, and logistics. The company’s earlier radioligand acquisitions and its 2024 acquisition of Mariana Oncology support that strategy.
• Strengthen the kidney and complement franchise. Novartis has been building around nephrology and complement biology through Fabhalta and the 2023 Chinook acquisition, which added pipeline assets relevant to kidney disease.
• Use bolt-on M&A to add platform depth or late-stage assets. Rather than pursuing broad diversification, Novartis has favored targeted deals such as MorphoSys and Mariana that deepen priority areas or add late-stage optionality.
• Improve productivity as a pure-play innovative medicines company. Following the Sandoz spin-off, Novartis has emphasized simplification, resource reallocation, and operating leverage. The goal is to make the organization faster and more focused while still funding substantial R&D investment.
• Use digital tools and AI to accelerate research and operations. Public statements by Novartis indicate continued investment in data science, AI-enabled research workflows, and productivity tools across the enterprise.

3. What Is the Business Model of Novartis?

Novartis sells branded prescription medicines. The company’s core economic model is to invest heavily in discovery, development, clinical trials, regulatory approval, manufacturing readiness, and launch capability, then earn returns during the period of patent and regulatory exclusivity.

What customers actually buy

Customers buy medicines that offer clinical benefit in specific diseases, usually backed by reimbursement support and physician adoption. In practical terms, health systems, wholesalers, specialty pharmacies, hospitals, and providers buy the product, but the underlying value proposition is measured by patient outcomes, clinical differentiation, safety, convenience, and total cost of care.

Recurring or repeat-driven versus one-time revenue

Much of Novartis’s model is repeat-driven. Chronic therapies such as Entresto, Cosentyx, Kesimpta, and Leqvio can generate recurring demand over long treatment durations. Oncology products can be episodic but still highly repeatable across treatment cycles and new patient starts. A smaller part of the portfolio has more one-time or limited-course economics, such as gene therapy.

How pricing power works

Novartis has pricing power when it offers meaningful clinical differentiation under patent protection, but that power is constrained by payers, national reimbursement systems, tender processes, and eventually generic or biosimilar competition. In pharmaceuticals, pricing power is real but never absolute. It is strongest when a product changes treatment standards or reduces downstream healthcare costs.

Why the business mix matters

The business mix matters because a chronic cardiometabolic brand, a hospital-administered oncology drug, and a rare-disease gene therapy have different margin profiles, selling models, reimbursement pathways, and durability. Novartis’s strategy is partly a mix-shift story: increasing the weight of newer, faster-growing innovative medicines while managing mature brands and loss-of-exclusivity risk.

What drives gross margin, operating margin, and cash generation

Gross margins are generally high because the key value driver is intellectual property rather than raw material cost. Operating margin depends heavily on R&D spending, launch spending, manufacturing complexity, legal and compliance costs, and the maturity of the portfolio. Cash generation is driven by blockbuster scale, high gross margins, and relatively modest capital intensity compared with industrial businesses, although specialized manufacturing investments for radioligands and advanced therapies can raise capital needs.

Revenue model

The revenue model is primarily unit sales of branded prescription medicines, recognized through pharmaceutical distribution channels. There can also be smaller contributions from royalties, collaborations, and milestone income, but Novartis is fundamentally a branded biopharma revenue model rather than a subscription or services model.

4. What Products and Services Does Novartis Sell?

Novartis sells prescription medicines. Its portfolio is best understood by therapeutic area rather than by broad corporate segment, because FY2024 external reporting reflects one operating segment: Innovative Medicines.

In FY2024, Novartis’s biggest commercial anchors still included large established brands such as Entresto and Cosentyx, but much of the company’s future growth narrative rests on newer products such as Kisqali, Kesimpta, Leqvio, Pluvicto, Scemblix, and Fabhalta. That distinction between current scale and future mix shift is important for understanding the business model of Novartis.

5. What Are the Key Competitors or Peers of Novartis?

Novartis competes product by product, indication by indication, rather than against one single rival across its whole portfolio. The closest competitors and peers are other large innovative biopharma companies with strength in oncology, immunology, cardiometabolic disease, neuroscience, or rare disease.

• Roche — A close Swiss peer with major positions in oncology, immunology, and diagnostics; often relevant in cancer and specialty care comparisons.
• Merck & Co. — A major oncology competitor, especially where immuno-oncology shapes treatment standards.
• AstraZeneca — Strong in oncology and cardiovascular-renal-metabolism, making it one of the most direct portfolio peers.
• Bristol Myers Squibb — Competes in oncology, hematology, and immunology; a relevant peer for specialist commercial execution.
• Johnson & Johnson Innovative Medicine — Broad-based rival in immunology, oncology, and neuroscience.
• AbbVie — Important comparator in immunology and hematologic oncology, especially where branded specialty franchises drive economics.
• Sanofi — A strong peer in immunology, rare disease, and specialty biopharma.
• Eli Lilly — Increasingly important because of its scale in immunology, neuroscience, and cardiometabolic disease.
• Pfizer — Broad innovative pharma competitor with reach in oncology, internal medicine, and hospital channels.
• Amgen — A relevant biologics-focused peer in inflammation, cardiovascular disease, and oncology.

In practice, Novartis also competes with smaller biotech companies, biosimilar entrants after loss of exclusivity, and disease-specific specialists. For a company like Novartis, the competitive set changes by molecule, line of therapy, and geography.

6. What Is the Marketing Strategy of Novartis?

Novartis’s marketing strategy is mostly science-led and access-led rather than consumer-packaged-goods style brand marketing. In pharmaceuticals, demand creation depends on clinical evidence, prescribing behavior, reimbursement, and physician confidence.

• Specialist-focused promotion. Many of Novartis’s highest-value products are prescribed by cardiologists, dermatologists, neurologists, oncologists, hematologists, nephrologists, and hospital-based specialists. Marketing therefore centers on scientific communication and field execution.
• Medical affairs and key opinion leader engagement. Congresses, publications, real-world evidence, and physician education are central to adoption, especially for launch brands and new indications.
• Market access as part of marketing. In pharma, reimbursement is inseparable from marketing. Novartis must persuade payers, health systems, and government bodies, not just prescribers.
• Patient support and adherence programs. Especially in chronic therapy and specialty medicines, support programs can improve initiation, persistence, and outcomes.
• Selective direct-to-consumer activity. In markets where regulations allow it, especially the United States, direct-to-consumer promotion can support awareness for certain brands, but it is not the company’s primary commercial lever.

Marketing is important at Novartis, but it is usually a supporting capability rather than the core moat. The real differentiators are clinical data, label breadth, physician trust, reimbursement access, and supply reliability.

7. What Are the Key Customer Segments of Novartis?

Novartis serves several customer groups at once, and the balance among them varies by product.

• Specialist physicians. Cardiologists, dermatologists, neurologists, oncologists, hematologists, and nephrologists are often the key prescribers for Novartis brands.
• Hospitals, cancer centers, and infusion sites. These matter especially for oncology, radioligand therapy, and advanced therapies that require specialized administration.
• Wholesalers, distributors, and specialty pharmacies. These intermediaries are crucial buyers in the pharmaceutical channel, even though they are not the ultimate clinical decision-makers.
• Commercial payers and government payers. Reimbursement decisions by insurers, Medicare and Medicaid programs, and national health systems are often decisive for access and net pricing.
• Patients and caregivers. Patients are the end users, and in some therapeutic areas patient education, support, and persistence materially affect outcomes and revenue durability.
• Health systems and national procurement bodies outside the U.S. In many markets, formulary inclusion and tender outcomes strongly influence commercial success.

Novartis is diversified across disease areas and customer types, but it remains heavily tied to large regulated healthcare systems. That makes market access and evidence generation just as important as traditional selling.

8. What Is the Sales Model of Novartis?

Novartis uses a hybrid pharmaceutical sales model that combines direct commercial teams, field medical teams, and distribution through wholesalers, specialty distributors, and pharmacies.

• Direct sales to providers and prescribers. Novartis deploys field teams that call on physicians, health systems, and treatment centers, especially in specialty care.
• Wholesaler and pharmacy channels. Many products move through major pharmaceutical wholesalers and then into retail or specialty pharmacy channels.
• Specialty distribution for complex therapies. Higher-complexity products often require tighter control over storage, reimbursement support, patient onboarding, or site readiness.
• Hospital and account management. For oncology and radioligand therapy, Novartis must work directly with treatment sites, not just prescribers, because administration capability and scheduling matter.
• Payer and market-access selling. Dedicated teams engage payers, pharmacy benefit managers, and health authorities to secure formulary access and reimbursement.

The structure of the sales model affects growth and pricing. A product sold mainly through specialty providers and reimbursed under complex benefit pathways requires more account management and access work than a more traditional chronic therapy. It also creates consultant opportunities in launch excellence, gross-to-net optimization, channel design, and site-of-care activation.

9. In What Geographies Does Novartis Operate?

Novartis operates globally. The company’s commercial footprint spans North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with the United States as its largest single market in FY2024.

Operationally, Novartis is anchored in Switzerland but has major management, research, and commercial hubs elsewhere. Basel remains the corporate center. The United States is strategically critical both commercially and organizationally, with important operations in New Jersey and Massachusetts. Novartis also has meaningful presence in major European markets, China, and Japan, which matter for launches, clinical development, and long-term growth.

Its manufacturing footprint is global as well, with networks in Europe, North America, and Asia supporting small molecules, biologics, sterile products, and specialized therapies. The geographic mix matters because pricing, reimbursement, regulatory timelines, and launch curves differ sharply across markets. A drug that scales quickly in the U.S. may require a slower access path in Europe or face different tender dynamics in emerging markets.

10. Who Are the Owners of Novartis?

Novartis is a publicly traded company. As of the FY2024 Annual Report, the company did not disclose a controlling shareholder. Ownership is broadly distributed among institutional and other public-market investors, with positions changing over time under Swiss shareholding disclosure rules. Novartis AG is listed in Switzerland under the ticker NOVN, and the company also has a U.S. American Depositary Receipt presence.

11. How Is Novartis Organized?

Legally, Novartis is organized around Novartis AG as the Swiss parent company with a global network of subsidiaries. From an external reporting standpoint, FY2024 reflects one operating segment: Innovative Medicines.

Practically, however, Novartis is managed through a matrix. The company combines therapeutic-area leadership, global functions, and regional commercial organizations. Core enterprise functions include Biomedical Research, Development, Operations, commercial organizations, finance, legal, and corporate support functions. Within the portfolio, management attention is often organized around disease areas and priority brands rather than around separate public segments.

This structure is important. Novartis wants the external simplicity of a focused medicines company, while retaining internal specialization by science, modality, geography, and launch franchise.

12. How Does Novartis Operate?

On a day-to-day basis, Novartis operates as a global drug discovery, development, manufacturing, and commercialization system.

1. Research and in-licensing. Novartis discovers molecules internally and supplements internal science through partnerships, licenses, and acquisitions.
2. Clinical development. The company runs global trials, builds evidence packages, and seeks regulatory approvals in multiple jurisdictions.
3. Technical operations and manufacturing. Once products approach launch, Novartis scales manufacturing, validates sites, manages quality systems, and prepares supply chains.
4. Commercial launch and market access. After approval, the company works through physician education, payer negotiations, account management, and channel distribution.
5. Lifecycle management. Novartis continues to operate brands through post-approval studies, label expansions, new geographies, formulation updates, and patent defense.

The operational complexities are considerable. Novartis must coordinate science, regulation, manufacturing, and commercial execution across many countries. The complexity is even higher for radioligand therapies, gene therapy, and other advanced modalities where production, logistics, and site readiness are part of the value chain. Day-to-day value creation therefore depends not just on discovering a good drug, but on reliably converting it into a global reimbursed product.

13. What Are the Growth Opportunities for Novartis?

The most plausible growth opportunities for Novartis are visible in both its current portfolio and its recent business development activity.

• Deeper penetration of current growth brands. Kisqali, Kesimpta, Leqvio, Pluvicto, Scemblix, and Fabhalta are central to the company’s near- to medium-term growth profile.
• Label expansions and earlier-line use. In oncology and specialty medicine, moving earlier in treatment algorithms can materially expand the addressable market.
• Cardiovascular prevention and kidney disease. Leqvio, Entresto, Fabhalta, and kidney-disease pipeline assets give Novartis a larger opportunity in chronic, high-prevalence disease areas.
• Radioligand therapy leadership. If Novartis can continue to build manufacturing and clinical depth, radioligands could remain a meaningful growth and differentiation platform.
• Geographic expansion. Large ex-U.S. markets still offer runway, though access and pricing dynamics differ by country.
• Selective M&A and licensing. Novartis has shown a willingness to buy assets or platforms that fit the focused-portfolio strategy.
• Productivity and mix improvement. Some of Novartis’s growth is financial as well as commercial: a better portfolio mix and higher operating efficiency can lift earnings faster than sales.

The constraints are also clear. Clinical failures, manufacturing bottlenecks, reimbursement pressure, loss of exclusivity, and regulatory delay can all slow the growth path. For Novartis, the opportunity is not simply “more products,” but better execution behind a relatively concentrated set of high-value assets.

14. What Is the History of Novartis?

Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two historic Swiss companies with roots going back to the nineteenth century. The merger created one of the world’s largest healthcare groups, combining pharmaceuticals, chemicals, and related businesses.

Over time, Novartis reshaped that portfolio significantly. It expanded into eye care through Alcon, then later spun Alcon off in 2019. It also undertook major asset swaps and portfolio moves to concentrate more on innovative medicines. In 2018, Novartis completed a series of strategically important acquisitions, including Advanced Accelerator Applications, Endocyte, and AveXis, which strengthened radioligand therapy and gene therapy capabilities. In 2020, it acquired The Medicines Company, bringing in inclisiran, now sold as Leqvio.

The biggest recent structural change came in 2023, when Novartis spun off Sandoz and became a pure-play innovative medicines company. In 2024, it continued to reshape the portfolio through acquisitions such as MorphoSys and Mariana Oncology. The history of Novartis is therefore not just a story of scientific development; it is also a story of repeated portfolio simplification toward a more focused strategy.

15. What Are the Key Suppliers to Novartis?

Suppliers are strategically important to Novartis, even though specific supplier names are not widely disclosed in detail. The most important supplier categories include active pharmaceutical ingredients and chemical intermediates, biologic raw materials, sterile fill-finish services, device components, packaging, clinical-trial materials, contract development and manufacturing organizations, and specialized logistics providers.

For Novartis, one supplier category deserves special mention: the ecosystem around radioligand therapy. That includes isotope-related inputs, highly controlled manufacturing steps, specialized packaging, and time-critical distribution. Supplier reliability matters because a disruption can affect clinical trials, commercial supply, regulatory compliance, or launch timing. As in most large pharma companies, Novartis likely uses a mix of internal production and external partners to balance resilience, cost, and speed.

16. What Are the Key Brands Owned by Novartis?

Brands matter at Novartis because prescribing decisions are tied to clinical evidence, indication breadth, safety profile, and physician familiarity. This is not consumer branding in the usual sense, but product brands are still economically important.

• Entresto — A flagship cardiovascular brand and one of Novartis’s largest products in FY2024.
• Cosentyx — A core immunology franchise with scale in inflammatory conditions.
• Kisqali — One of Novartis’s most important oncology growth brands, especially in breast cancer.
• Kesimpta — A major neuroscience growth driver in multiple sclerosis.
• Leqvio — Strategically important because of its potential in cholesterol management and cardiovascular prevention.
• Pluvicto — Central to Novartis’s radioligand oncology strategy.
• Scemblix — A targeted hematology oncology brand with meaningful growth potential.
• Fabhalta — A newer rare-disease and complement-pathway brand that matters to the company’s kidney and specialty strategy.
• Lutathera — An earlier radioligand asset that helped establish Novartis’s position in the modality.
• Zolgensma — A notable gene therapy brand; strategically important even though its revenue profile differs from chronic treatments.

At Novartis, brands are important, but their durability depends more on patents, outcomes, reimbursement, and evidence than on mass-market advertising.

17. How Is Novartis Using AI?

Novartis has publicly discussed AI and data science as important enablers across research, development, and operations. In a company like Novartis, AI is not a single product initiative; it is a portfolio of use cases.

• Drug discovery and target selection. AI and machine learning can help prioritize targets, analyze biological data, and improve hit identification.
• Clinical development. AI tools can support protocol design, patient matching, site selection, and analysis of trial data.
• Manufacturing and quality. Predictive analytics can improve yield, maintenance planning, deviation management, and supply reliability.
• Commercial and enterprise productivity. Generative AI can support medical writing, knowledge retrieval, content drafting, coding, and other knowledge-work processes.

The important distinction is between live and scaled uses versus aspirational ones. AI-enabled analytics in research and operations are already part of large pharma practice. Broader generative AI transformation is still being scaled and governed. For Novartis, the strategic value of AI is less about headlines and more about making R&D and operations faster, more informed, and more productive.

18. How Does the Supply Chain of Novartis Function?

Novartis’s supply chain begins with sourcing active ingredients, biologic inputs, devices, packaging, and outsourced manufacturing services. These inputs move into a global network of internal and external manufacturing sites, where products are produced, tested, released, and prepared for distribution under stringent good manufacturing practice requirements.

From there, supply-chain design depends on the product. Traditional oral medicines can move through more standard pharmaceutical distribution channels. Biologics and sterile injectables require tighter temperature control and batch management. Radioligand therapies require an even more specialized model because the product, manufacturing schedule, treatment site, and patient appointment are tightly linked. That makes reliability, schedule discipline, and logistics visibility strategically important.

Supply-chain performance matters at Novartis for three reasons. First, regulatory compliance is non-negotiable. Second, shortages or quality issues can delay revenue and damage physician trust. Third, new product launches depend on having the right capacity in the right modality. For a company pushing into radioligands and other specialized therapies, supply chain is not a back-office function; it is part of the competitive advantage.

19. What Are the Key Assets of Novartis?

Novartis’s most important assets are a mix of intangible and physical assets.

• Intellectual property. Patents, know-how, and regulatory exclusivities are central to value creation.
• Pipeline and clinical data. The future value of Novartis depends heavily on the quality of its development pipeline and the evidence behind it.
• Manufacturing network. Specialized facilities for small molecules, biologics, sterile products, radioligands, and advanced therapies matter operationally and strategically.
• Global approvals and regulatory dossiers. Approved labels and the supporting regulatory infrastructure are valuable barriers to entry.
• Commercial franchises and physician relationships. Large established brands and specialist relationships provide launch leverage for adjacent products.
• Financial capacity. Strong cash generation gives Novartis room to invest in R&D, capacity, dividends, buybacks, and targeted acquisitions.

Pharma is asset-intensive in a different way from airlines or mining. The key assets are not only plants and equipment, but also patents, data, manufacturing know-how, and long-cycle scientific programs. For Novartis, those assets create both barriers to entry and high operating leverage when a product succeeds.

20. What Is the R&D Strategy of Novartis?

R&D is at the center of Novartis’s strategy. The company’s approach is to concentrate scientific resources in areas where it believes it has disease expertise, modality capability, and meaningful commercial potential. Rather than spreading research broadly across every major disease category, Novartis has narrowed the portfolio around selected therapeutic areas and technology platforms.

In practice, that means combining internal discovery with external innovation. Novartis does not rely solely on its own laboratories; it also licenses assets, partners with biotech companies, and acquires programs that fit priority areas. This is visible in deals that strengthened radioligands, gene therapy, kidney disease, and hematology-oncology.

Another feature of the R&D strategy is translational focus. Novartis has emphasized moving from biology to high-conviction programs with clearer clinical differentiation. That reduces, though does not eliminate, the risk of costly late-stage attrition. Recent innovation themes associated with Novartis include radioligand therapy, RNA-based approaches, complement biology, cardiovascular prevention, and targeted oncology. For investors and operating executives alike, the key point is that Novartis’s growth case depends more on R&D productivity than on sheer scale.

21. What Is the Finance Strategy of Novartis?

Novartis’s finance strategy is built around the economics of a focused branded biopharma company: high gross margins, substantial R&D investment, strong cash generation from successful products, and disciplined capital allocation. Since the Sandoz spin-off, management has presented Novartis as a simpler, higher-margin enterprise with a clearer use of cash.

At a high level, capital allocation supports four priorities. First, reinvest in internal R&D and launch-related capacity. Second, pursue targeted business development and acquisitions that fit core therapeutic areas or platform technologies. Third, maintain an attractive dividend profile consistent with Swiss large-cap practice. Fourth, return excess capital through share repurchases when appropriate.

Margin improvement is also part of the finance strategy. Novartis has emphasized productivity and simplification, not just top-line growth. That matters because even in a strong pharma portfolio, earnings quality depends on controlling launch costs, manufacturing complexity, and overhead. Working capital is usually less constraining than in many industrial businesses, but inventory, channel terms, and launch builds still matter. In short, Novartis is trying to use the cash flow of a mature large-cap pharma company to fund the growth profile of a more focused innovation engine.

22. What Major Acquisitions Has Novartis Made?

Acquisitions have been an important, but selective, part of Novartis’s strategy. The company does not look like a serial roll-up. Instead, it has used M&A to acquire platforms, late-stage assets, or leadership positions in chosen modalities.

• Advanced Accelerator Applications (2018) — Expanded Novartis’s position in radioligand therapy and added Lutathera.
• Endocyte (2018) — Added the asset that became Pluvicto, reinforcing the radioligand oncology franchise.
• AveXis (2018) — Brought in gene therapy capabilities and Zolgensma.
• The Medicines Company (2020) — Added inclisiran, now commercialized as Leqvio, strengthening cardiovascular prevention.
• Gyroscope Therapeutics (2022) — Added retinal gene-therapy capabilities and pipeline optionality.
• Chinook Therapeutics (2023) — Strengthened Novartis’s kidney disease pipeline.
• MorphoSys (2024) — Added late-stage hematology-oncology assets and deepened the oncology portfolio.
• Mariana Oncology (2024) — Expanded radioligand therapy capabilities and pipeline depth.

The pattern is consistent: Novartis uses M&A to sharpen the focused medicines strategy, not to rebuild a diversified conglomerate. That is a meaningful distinction when evaluating the company’s portfolio and capital allocation discipline.

23. How Companies Like Novartis Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Novartis engage Umbrex when they want that caliber of problem solving and execution support, but do not need a full consulting team with the associated overhead. Umbrex consultants work across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI. For a focused innovative medicines company like Novartis, the most relevant projects are typically linked to launches, portfolio choices, specialized operations, and productivity.

• Launch excellence for priority brands — support country-level launch planning, field-force sizing, and KPI design for brands such as Fabhalta, Scemblix, Leqvio, or Pluvicto.
• Radioligand therapy network expansion — map treatment-site capacity, referral flows, scheduling bottlenecks, and go-live requirements for new radioligand indications.
• Portfolio prioritization — assess where Novartis should concentrate commercial and medical resources across oncology, immunology, neuroscience, and cardiovascular-renal-metabolism.
• Market access and pricing analytics — build payer segmentation, gross-to-net models, and reimbursement playbooks for major markets.
• Manufacturing and supply-chain resilience — evaluate single-source risks, outsourcing strategy, and inventory policies for critical APIs, sterile products, or specialized therapy platforms.
• AI use-case roadmaps — identify and prioritize high-value AI applications in clinical operations, medical writing, manufacturing quality, and enterprise knowledge work.
• Post-acquisition integration — support integration planning and synergy capture for acquired assets, teams, and pipelines from deals such as MorphoSys, Chinook, or Mariana.
• Commercial model redesign — redesign how field teams, key-account managers, and medical affairs coordinate in specialist and hospital-centered channels.
• Productivity and operating-model simplification — identify SG&A savings, decision-rights improvements, and organizational changes consistent with Novartis’s focused-company strategy.
• Global expansion strategy — adapt launch and access strategies for China, Japan, Europe, and selected emerging markets where reimbursement pathways and treatment-site economics differ materially from the U.S.